SCHEMBL15215674

SCHEMBL15215674

CC(C)CCCN(C)C(=O)CC(C)C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.40
KDM4A O75164 1/20 0.40
PHF8 Q9UPP1 1/20 0.40
KDM2A Q9Y2K7 1/20 0.40
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
ALDH1A1 P00352 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
BLM P54132 1/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA4 P43681 1/20 0.34
CA2 P00918 1/20 0.33
CA1 P00915 1/20 0.32
TACR1 P25103 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12197973 0.87 ALDH1A1 (0.40) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL24813826 0.84 KDM4C (0.34) KDM4CKDM4APHF8KDM2A
SCHEMBL13797616 0.83 SMN1; SMN2 (0.42) KDM4CPHF8ALDH1A1TDP1CA1
SCHEMBL15216257 0.83 KDM4C (0.40) KDM4CKDM4APHF8KDM2ANOS3
SCHEMBL19757978 0.83 ALDH1A1 (0.36) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL13895340 0.82 ALDH1A1 (0.34) NOS3NOS1NOS2ALDH1A1TDP1
SCHEMBL17660535 0.82 KDM4C (0.39) KDM4CKDM4APHF8KDM2ANOS3
SCHEMBL26752289 0.80 KDM4C (0.41) KDM4CKDM4APHF8KDM2ANOS3
SCHEMBL29299625 0.79 USP2 (0.33) KDM4CKDM4APHF8KDM2AALDH1A1
SCHEMBL17660529 0.79 KDM4C (0.37) KDM4CKDM4APHF8KDM2ANOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9040519-B2 Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-26 US disclosed
US-20130225558-A1 FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225558-A1 FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE HTR4, HTR3B, HTR2C KDM4C 1118/4885KDM4A 1152/4885PHF8 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.